Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy
dc.contributor.author | Bauer, Todd M. | en_US |
dc.contributor.author | El‐rayes, Bassel F. | en_US |
dc.contributor.author | Li, Xiaobai | en_US |
dc.contributor.author | Hammad, Nazik | en_US |
dc.contributor.author | Philip, Philip A. | en_US |
dc.contributor.author | Shields, Anthony F. | en_US |
dc.contributor.author | Zalupski, Mark M. | en_US |
dc.contributor.author | Bekaii‐saab, Tanios | en_US |
dc.date.accessioned | 2013-02-12T19:01:20Z | |
dc.date.available | 2014-03-03T15:09:25Z | en_US |
dc.date.issued | 2013-01-15 | en_US |
dc.identifier.citation | Bauer, Todd M.; El‐rayes, Bassel F. ; Li, Xiaobai; Hammad, Nazik; Philip, Philip A.; Shields, Anthony F.; Zalupski, Mark M.; Bekaii‐saab, Tanios (2013). "Carbohydrate antigen 19â 9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabineâ containing chemotherapy." Cancer 119(2): 285-292. <http://hdl.handle.net/2027.42/96409> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/96409 | |
dc.description.abstract | BACKGROUND: Carbohydrate antigen 19‐9 (CA19‐9) is a widely used biomarker in pancreatic cancer. There is no consensus on the interpretation of the change in CA19‐9 serum levels and its role in the clinical management of patients with pancreatic cancer. METHODS: Individual patient data from 6 prospective trials evaluating gemcitabine‐containing regimens from 3 different institutions were pooled. CA19‐9 values were obtained at baseline and after successive cycles of treatment. The objective of this study was to correlate a decline in CA19‐9 with outcomes while undergoing treatment. RESULTS: A total of 212 patients with locally advanced (n = 50) or metastatic (n = 162) adenocarcinoma of the pancreas were included. Median baseline CA19‐9 level was 1077 ng/mL (range, 15‐492,241 ng/mL). Groups were divided into those levels below (low) or above (high) the median. Median overall survival (mOS) was 8.7 versus 5.2 months ( P = .0018) and median time to progression (mTTP) was 5.8 versus 3.7 months ( P = .082) in the low versus high groups, respectively. After 2 cycles of chemotherapy, up to a 5% increase versus ≥ 5% increase in CA19‐9 levels conferred an improved mOS (10.3 vs 5.1 months, P = .0022) and mTTP (7.5 vs 3.5 months, P = 0.0005). CONCLUSIONS: In patients who have advanced pancreatic cancer treated with gemcitabine‐containing regimens baseline CA19‐9 is prognostic for outcome. A decline in CA19‐9 after the second cycle of chemotherapy is not predictive of improved mOS or mTTP; thus, CA19‐9 decline is not a useful surrogate endpoint in clinical trials. Clinically, a ≥ 5% rise in CA19‐9 after 2 cycles of chemotherapy serves as a negative predictive marker. Cancer 2013. © 2012 American Cancer Society. Baseline carbohydrate antigen 19‐9 (CA19‐9) is prognostic for outcomes in patients with pancreatic adenocarcinoma. Change in CA19‐9 serum level up to a 5% increase from baseline remains predictive for response to gemcitabine‐containing therapy, and thus should be considered a negative predictor. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Pancreatic | en_US |
dc.subject.other | Prognostic | en_US |
dc.subject.other | Predictive | en_US |
dc.subject.other | Outcomes | en_US |
dc.subject.other | Carbohydrate Antigen 19‐9 | en_US |
dc.subject.other | Gemcitabine | en_US |
dc.title | Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio | en_US |
dc.contributor.affiliationother | Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Avenue; Columbus, OH 43210; Fax: (614) 293‐9469 | en_US |
dc.contributor.affiliationother | Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan | en_US |
dc.contributor.affiliationother | Department of Oncology, Cancer Center of Southeastern Ontario, Queens University, Kingston, Canada | en_US |
dc.contributor.affiliationother | Center for Biostatistics, The Ohio State University, Columbus, Ohio | en_US |
dc.contributor.affiliationother | Division of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia | en_US |
dc.identifier.pmid | 22786786 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/96409/1/27734_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.27734 | en_US |
dc.identifier.source | Cancer | en_US |
dc.identifier.citedreference | Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361 ‐ 387. | en_US |
dc.identifier.citedreference | Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19‐9 as tumor marker in patients with pancreatic cancer. Oncology. 2006; 70: 255 ‐ 264. | en_US |
dc.identifier.citedreference | von Rosen A, Linder S, Harmenberg U, Pegert S. Serum levels of CA 19‐9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas. 1993; 8: 160 ‐ 165. | en_US |
dc.identifier.citedreference | Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19‐9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987; 47: 5501 ‐ 5503. | en_US |
dc.identifier.citedreference | Castellanos E, Berlin J, Cardin DB. Current treatment options for pancreatic carcinoma. Curr Oncol Rep. 2011; 13: 195 ‐ 205. | en_US |
dc.identifier.citedreference | Hammad N, Heilbrun LK, Philip PA, et al. CA19‐9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine‐based chemotherapy. Asia Pac J Clin Oncol. 2010; 6: 98 ‐ 105. | en_US |
dc.identifier.citedreference | Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19‐9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005; 93: 740 ‐ 743. | en_US |
dc.identifier.citedreference | Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA 19‐9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002; 32: 35 ‐ 41. | en_US |
dc.identifier.citedreference | Reni M, Cereda S, Balzano G, et al. Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 2009; 115: 2630 ‐ 2639. | en_US |
dc.identifier.citedreference | Hess V, Glimelius B, Grawe P, et al. CA 19‐9 tumour‐marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008; 9: 132 ‐ 138. | en_US |
dc.identifier.citedreference | Wasan HS, Springett GM, Chodkiewicz C, et al. CA 19‐9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer. 2009; 101: 1162 ‐ 1167. | en_US |
dc.identifier.citedreference | Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19‐9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer. 1998; 77: 325 ‐ 328. | en_US |
dc.identifier.citedreference | Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V. Decrease of CA 19‐9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000; 82: 1013 ‐ 1016. | en_US |
dc.identifier.citedreference | Stemmler J, Stieber P, Szymala AM, et al. Are serial CA 19‐9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie. 2003; 26: 462 ‐ 467. | en_US |
dc.identifier.citedreference | Ziske C, Schlie C, Gorschlüter M, et al. Prognostic value of CA 19‐9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003; 89: 1413 ‐ 1417. | en_US |
dc.identifier.citedreference | Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19‐9 response as a surrogate for clinical outcome in patients receiving fixed‐dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005; 93: 195 ‐ 199. | en_US |
dc.identifier.citedreference | Martin LK, Li X, Kim SE, et al. A multi‐center phase II study of the combination of bevacizumab, fixed dose rate gemcitabine, and infusional 5‐fluorouracil in patients with advanced pancreas cancer. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; April 18‐22, 2009; Denver, CO. Philadelphia, PA: AACR; 2009. Abstract 4500. | en_US |
dc.identifier.citedreference | Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001; 92: 569 ‐ 577. | en_US |
dc.identifier.citedreference | Hill ME, Li X, Kim S, et al. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2011; 67: 511 ‐ 517. | en_US |
dc.identifier.citedreference | El‐Rayes BF, Zalupski MM, Shields AF, et al. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol. 2003; 21: 2920 ‐ 2925. | en_US |
dc.identifier.citedreference | El‐Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005; 23: 583 ‐ 590. | en_US |
dc.identifier.citedreference | Kosuri KV, Bekaii‐Saab TS, Bender J, et al. Disrupting TNF signaling in pancreatic cancer: A phase I/II clinical study in patients with advanced disease [Abstract]. Proceedings of the 2005 ASCO Annual Meeting. J Clin Oncol. 2005; 23 ( suppl ): abstract 4103. | en_US |
dc.identifier.citedreference | Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19‐9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008; 37: 269 ‐ 274. | en_US |
dc.identifier.citedreference | Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab‐paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29: 4548 ‐ 4554. | en_US |
dc.identifier.citedreference | Mamon HJ, Niedzwiecki D, Hollis D, et al; Cancer and Leukemia Group B. A phase 2 trial of gemcitabine, 5‐fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma: cancer and Leukemia Group B (CALGB) 80003. Cancer. 2011; 117: 2620 ‐ 2628. | en_US |
dc.identifier.citedreference | Sudo K, Yamaguchi T, Nakamura K, et al. Phase II study of S‐1 in patients with gemcitabine‐resistant advanced pancreatic cancer. Cancer Chemother Pharmacol. 2011; 67: 249 ‐ 254. | en_US |
dc.identifier.citedreference | Lipton A, Campbell‐Baird C, Witters L, Harvey H, Ali S. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol. 2010; 44: 286 ‐ 288. | en_US |
dc.identifier.citedreference | Small W Jr, Berlin J, Freedman GM, et al. Full‐dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008; 26: 942 ‐ 947. | en_US |
dc.identifier.citedreference | Swets JA, Pickett RM. Evaluation of Diagnostic Systems: Methods From Signal Detection Theory. New York: Academic Press; 1982. | en_US |
dc.identifier.citedreference | Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007; 25: 2212 ‐ 2217. | en_US |
dc.identifier.citedreference | Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24: 3946 ‐ 3952. | en_US |
dc.identifier.citedreference | Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan‐gemcitabine (IG) with gemcitabine (G) monotherapy as first‐line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006; 95: 587 ‐ 592. | en_US |
dc.identifier.citedreference | Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009; 27: 5513 ‐ 5518. | en_US |
dc.identifier.citedreference | Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group‐directed intergroup trial S0205. J Clin Oncol. 2010; 28: 3605 ‐ 3610. | en_US |
dc.identifier.citedreference | Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010; 28: 3617 ‐ 3622. | en_US |
dc.identifier.citedreference | Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225 ‐ 249. | en_US |
dc.identifier.citedreference | Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996; 78 ( 3 suppl ): 627 ‐ 632. | en_US |
dc.identifier.citedreference | Brambs HJ, Claussen CD. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy. 1993; 25: 58 ‐ 68. | en_US |
dc.identifier.citedreference | Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science. 1981; 212: 53 ‐ 55. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.